The severity, duration, and reversibility of pentamidine induced bronchial narrowing was studied with and without pretreatment with nebulised terbutaline 10 mg in an open study of 40 patients seropositive for the human immunodeficiency virus (HIV). All subjects received pentamidine 300 mg in 5 ml water via an Acorn System 22 jet nebuliser. The forced expiratory volume in one second (FEV1) fell in all 20 patients given pentamidine alone, the mean maximum fall being 20-6%. In the 20 patients given pentamidine preceded by nebulised terbutaline the mean maximum fall in FEV, was 4%; three subjects had a fall in FEV, of more than predicted (range 70-141%), pentamidine + terbutaline group 106% predicted (range 65-133%)). There was no significant difference in FEV, between patients having primary and those having secondary pneumocystis pneumonia prophylaxis (107% v 95% predicted).
Methods
We studied 40 homosexual, HIV positive men (mean age (range 24-56) years) with no past history of chronic lung disease. Seventeen were cigarette smokers. All were receiving fortnightly treatment with pentamidine isethionate (Pentacarinat, Rhone-PoulencRorer: 300 mg in 5 ml of water) delivered by an Acorn System 22 jet nebuliser (Medic-Aid, Pagham, Sussex) predicted (range 70-141%), pentamidine + terbutaline group 106% predicted (range 65-133%)). There was no significant difference in FEV, between patients having primary and those having secondary pneumocystis pneumonia prophylaxis (107% v 95% predicted).
EFFECT OF PENTAMIDINE WITH AND WITHOUT TERBUTALINE
FEV, fell in all 20 subjects treated with pentamidine alone (mean maximum fall 21%, range 8-62%; p < 0-001). The mean fall in FEV, was maximal five minutes after inhalation of pentamidine (mean fall 19%; p < 0-001), and it was still reduced by 16% at 30 minutes (figure). The fall in FEV, varied widely between patients; a fall of 15% or more occurred in 13 of the 20 patients at some time after they had pentamidine. The response was no different in patients having primary and secondary pneumocystis pneumonia prophylaxis, nor did the number of previous episodes of pneumocystis pneumonia make any difference.
There was a fall in FEV, in most of the group pretreated with terbutaline (mean maximum change in FEV, = -4-3%, range + 16-6 to -22-6%, p < 0-005) but it was less than that seen with pentamidine alone (p < 0 001). Both moieties of pentamidine isethionate have been implicated in the genesis of airway narrowing, though in one study pentamidine isethionate and pentamidine gluconate caused no difference in toxicity,6 suggesting that pentamidine rather than isethionate is responsible for bronchial narrowing. The pH and osmolality of the nebulised solution might also be important.7 The pH of pentamidine isethionate is 4-5-6-0 (data on file, RhonePoulenc-Rorer), which is sufficiently acidic to cause bronchial irritation. Adjustment of this pH, possibly by inert buffers, may reduce unwanted effects. When pentamidine is made into solution as recommended by the manufacturer it is sufficiently hypotonic to cause airway narrowing. The osmolality ranges from 128 mosmol/kg (for 300 mg pentamidine isethionate in 10 ml water) to 294 mosmol/kg (for 300 mg pentamidine isethionate in 3 ml water) (Leigh et al, unpublished observations).
Thus pretreatment with 10 mg nebulised terbutaline reduced the severity of falls in FEV1 seen with nebulised pentamidine but did not totally abolish them. Whether modification of the pentamidine solution and its mode of administration will reduce side effects more requires further investigation.
